The team is still exploring why that happens, but Spencer suspects that CDK4 and CDK6 may stand in the shadows throughout the cell cycle, ready to jump in and assist when CDK2 is impaired. She said ...

Citation: Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in some breast cancer (2022, September 16) retrieved 16 May 2025 from https ...

According to Fang et al. (2022), Physalin B suppressed the expression of cell cycle regulatory proteins, including cyclin D1, cyclin D3, CDK4, CDK6 and cyclin E, as well as increasing the protein ...

DelveInsight's CDK4/6 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CDK4/6 inhibitors, market share of individual therapies, and ...

A real-world analysis shows "meaningful" overall survival benefits when a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor is added to endocrine therapy for older women with HR-positive/HER2 ...

Results showed the addition of CDK4/6 inhibitors in the first-line vs. second-line setting did not lead to a statistically significant nor clinically relevant PFS benefit (HR = 0.87; 95% CI, 0.74 ...

Early-phase trials hinted that camizestrant plus a CDK4/6 inhibitor could postpone tumor growth in people whose cancers already carried an ESR1 mutation. HR+, HER2- Advanced Breast Cancer.

More information: Inbal Shamir et al, Differential silencing of STAT3 isoforms leads to changes in STAT3 activation, Oncotarget (2023). DOI: 10.18632/oncotarget.28412 Journal information: Oncotarget ...

CDK4/6 Inhibitors in Breast Cancer: New Populations, Different Settings — Maryam Lustberg, MD, details three posters she was a discussant on at ASCO 2023.

BUFFALO, NY — May 22, 2025 — A new review was published in Volume 12 of Oncoscience on May 8, 2025, titled “The chemopreventive effects of native Brazilian plants on stomach cancer: A review ...

Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.